Besides, a CAF-related gene osteopontin (OPN) was also found to be a predictive biomarker for metastatic CRC patients treated with first-line FOLFIRI/bevacizumab in two independent randomized phase III trials (Puccini et al., 2018). The gene discussed is SPP1; the disease is colorectal carcinoma.